The Leukemia & Lymphoma Society’s (LLS) Equity in Access Research Program aims to build evidence for effective interventions to increase therapeutic cancer clinical trial accrual, focusing on promoting access for patients from underrepresented groups. This funding opportunity supports research that guides changes in healthcare policy and practice, ensuring that all blood cancer patients can access optimal treatment and resources, regardless of race, ethnicity, disability, sexual orientation, gender identity, socioeconomic status, geography, preferred language, or other factors. The program encourages multidisciplinary research teams and emphasizes reducing health disparities linked to social and economic disadvantages. Applications are open to researchers from public or nonprofit institutions in the U.S. or its territories, with a focus on projects with a maximum duration of 5 years and total funding up to $2.5 million.

The grant application process involves submitting a Letter of Intent by September 12, 2024, and invited full proposals by January 30, 2025. The research must be led by a Principal Investigator affiliated with a public or nonprofit institution, with support for early-career investigators through experienced co-investigators.